A2 Biotherapeutics – a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to target tumor cells and protect normal cells selectively – announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital.
The proceeds will fund the company’s three clinical development programs and the advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod platform technology.
A2 Bio is currently conducting two seamless phase 1/2 clinical studies: EVEREST-1 studying A2B530 for pancreatic, lung and colorectal cancers by targeting carcinoembryonic antigen (CEA); and EVEREST-2 studying A2B694 for pancreatic, ovarian, lung, colorectal and mesothelioma cancers by targeting mesothelin (MSLN). And patients are enrolled in EVEREST-1 and EVEREST-2 through the BASECAMP-1 prescreening study. BASECAMP-1 utilizes AI-enabled precision diagnostics as a cost-effective, high-yield approach to identify eligible patients for all A2 Bio clinical studies.
A2 Biotherapeutics (established in 2018) is a fully integrated discovery, development and manufacturing company based in Agoura Hills, Calif. And A2 Bio plans to direct the Series C funds to support the company’s three clinical studies, as well as to advance preclinical programs using its Tmod platform for potential clinical targets representing significant unmet needs in cancer and beyond.
KEY QUOTES:
“We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers. This funding will enable us to continue ongoing clinical development of our CAR-T cell therapies as well as fund the potential next phase of development.”
– Jim Robinson, chief executive officer of A2 Bio
